Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. A whole-genome shRNA screen identifies combinatorial drug targets.
  • Fig. S2. Combination of mTOR inhibitors with IGF1R and MEK inhibitors reduces the viability of KRAS-mutant NSCLC cells.
  • Fig. S3. KRAS-mutant cells show increased sensitivity to the combination of mTOR, IGF1R, and MEK inhibitors.
  • Fig. S4. Combination of IGF1R with mTOR inhibitors blocks PI3K/AKT and mTOR pathways.
  • Fig. S5. mTOR inhibition activates the IGF1R pathway in KRAS-mutant cells.
  • Fig. S6. Combination of mTOR, IGF1R, and MEK inhibitors results in regression of KRAS-driven lung tumors.
  • Fig. S7. Drug combinations with a KRAS-G12C inhibitor cause inhibition of viability in KRAS-mutant cells.
  • Fig. S8. Combination of KRAS-G12C inhibitor, IGF1R, and mTOR inhibitors is effective in vivo.
  • Reference (55)

[Download PDF]

Other Supplementary Material for this manuscript includes the following: